Presentation is loading. Please wait.

Presentation is loading. Please wait.

Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.

Published byColin Gavin Shields Modified over 8 years ago

Similar presentations

Presentation on theme: "Yunoki K et al. Atherosclerosis 2011 Epub Apr 22."— Presentation transcript:

1 Yunoki K et al. Atherosclerosis 2011 Epub Apr 22

2 Baseline clinical characteristics Yunoki K et al. Atherosclerosis 2011 Epub Apr 22

3 Laboratory data and endothelial function during a fasting state before and after treatment for 4 weeks in the ezetimibe and control groups Yunoki K et al. Atherosclerosis 2011 Epub Apr 22

4 (A–C) Postprandial changes in serum TG, RLP-C and apoB-48 levels and the AUC for postprandial serum TG, RLP-C and apoB-48 levels before and after treatment for 4 weeks in the ezetimibe and control groups (D) Postprandial changes in %FMD and changes in maximum reduction of %FMD after the cookie test (max Δ%FMD) before and after treatment for 4 weeks in the ezetimibe and control groups Open bar indicates ezetimibe group; solid bar, control group Data are expressed as mean ± SE. *P < 0.05, vs. before treatment Yunoki K et al. Atherosclerosis 2011 Epub Apr 22

5 Postprandial changes in serum TG levels and the AUC for postprandial serum TG levels before and after treatment for 4 weeks in the ezetimibe and control groups (open bar indicates ezetimibe group; solid bar, control group) Data are expressed as mean ± SE. *P < 0.05, vs. before treatment

6 Yunoki K et al. Atherosclerosis 2011 Epub Apr 22 Postprandial changes in serum RLP-C levels and the AUC for postprandial serum RLP-C levels before and after treatment for 4 weeks in the ezetimibe and control groups (open bar indicates ezetimibe group; solid bar, control group) Data are expressed as mean ± SE. *P < 0.05, vs. before treatment

7 Yunoki K et al. Atherosclerosis 2011 Epub Apr 22 Postprandial changes in serum apoB-48 levels and the AUC for postprandial serum apoB-48 levels before and after treatment for 4 weeks in the ezetimibe and control groups (open bar indicates ezetimibe group; solid bar, control group) Data are expressed as mean ± SE. *P < 0.05, vs. before treatment

8 Yunoki K et al. Atherosclerosis 2011 Epub Apr 22 Postprandial changes in %FMD and changes in maximum reduction of %FMD after the cookie test (max Δ%FMD) before and after treatment for 4 weeks in the ezetimibe and control groups Data are expressed as mean ± SE. *P < 0.05, vs. before treatment

Download ppt "Yunoki K et al. Atherosclerosis 2011 Epub Apr 22."

Similar presentations

The concept of Diabetes & CV risk: A lifetime risk challenge Vascular function as an early sign of trouble: How can the inhibition of cholesterol absorption.

The concept of Diabetes & CV risk: A lifetime risk challenge Vascular function as an early sign of trouble: How can the inhibition of cholesterol absorption.
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.
Downloaded from www.ezetrol.aewww.ezetrol.ae Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.
Pramlintide – An analog of amylin that overcomes the tendency of human amylin to: Aggregate, form insoluble particles Adhere to surfaces – Pharmacokinetic.

Pramlintide – An analog of amylin that overcomes the tendency of human amylin to: Aggregate, form insoluble particles Adhere to surfaces – Pharmacokinetic.
VBWG BRAVER Trial BRachial Artery Vascular Endothelium Reactivity Study A substudy of PROVE IT-TIMI 22.

VBWG BRAVER Trial BRachial Artery Vascular Endothelium Reactivity Study A substudy of PROVE IT-TIMI 22.
-7 -6 -5 -4 -3 -2 0 03691215182124 Treatment month Adjusted mean change in IPSS from baseline (ITT, LOCF) Tamsulosin -4.8 -4.5 -4.4 -4.3 -4.5 -4.4 -4.7.

Treatment month Adjusted mean change in IPSS from baseline (ITT, LOCF) Tamsulosin
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.
Infusion of Hi-Xen reduces the iAUCs for gastric emptying and postprandial glucose levels in humans with NGT, IGT, and T2DM. Infusion of Hi-Xen reduces.

Infusion of Hi-Xen reduces the iAUCs for gastric emptying and postprandial glucose levels in humans with NGT, IGT, and T2DM. Infusion of Hi-Xen reduces.
Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.

Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.
Westerweel PE et al. Eur Heart J 2008;29:

Westerweel PE et al. Eur Heart J 2008;29:
Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride.

Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride.
Oxford Niacin Trial.

Oxford Niacin Trial.
IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.

IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45:380-388 (DOI:

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )

Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Similar presentations

Ads by Google